GU Cancer

A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial

---

S1931

Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

---

S1823

A Prospective Observational Cohort Study to Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

---

EA8185

Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive BladdeR CancEr (INSPIRE)

---

A031803

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

---

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

---

A031704

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

---

S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

---

2018-01 (MBMC only) (temporarily closed)

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

---

A031702 (Penile Cohort Suspended 3/13/20/ Miscellaneous GU Tract Variants Cohort suspended 7/20/20/ Small Cell Carcinoma/ Neuroendocrine of the Bladder Cohort suspended 4/21/21/ Adenocarcinoma of the Bladder Cohort Closed 11/9/20/ Renal Medullary Cohort suspended 6/23/21))

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

---